{"schema_version":"secwatch.filing_event.v1","accession":"0001821586-24-000019","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.385757+00:00","generated_at":"2026-06-02T19:47:46.662218+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MoonLake Q1 cash $547.1M; positive FDA/EMA feedback for Phase 3 sonelokimab in HS","bullets":["Cash and equivalents $547.1M at March 31, 2024, expected to fund operations to end of 2026.","R&D expense $13.0M in Q1 (up from $8.1M prior Q) due to trial initiations; G&A $6.8M.","Positive FDA and EMA feedback for Phase 3 VELA program in HS; topline data expected mid-2025.","ARGO Phase 2 in PsA: up to 52% ACR50+PASI100 and 61% MDA at week 24, suggesting best-in-class profile.","Plans to initiate four additional trials in PPP, juvenile HS, seronegative spondyloarthritis in 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001821586-24-000019","json":"https://secwatch.observer/filing/0001821586-24-000019.json","markdown":"https://secwatch.observer/filing/0001821586-24-000019.md","text":"https://secwatch.observer/filing/0001821586-24-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000182158624000019/0001821586-24-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000182158624000019/mnlk-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:47:46.662218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d0fe96b80a9f72913fc77f1e36d8ab6c8602b60a","claim":"MoonLake Immunotherapeutics reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000182158624000019/0001821586-24-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}